The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Tafasitamab is a humanized monoclonal antibody that binds to the CD19 antigen, which is expressed in tumor cells from patients with diffuse large B-cell lymphoma (DLBCL). On June 24, 2021, a positive opinion for a conditional marketing authorization was issued by the European Medicines Agency (EMA)’...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, Julio, Papadouli, Irene, Sarac, Sinan B., Moreau, Alexandre, Hovgaard, Doris, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601272/
https://www.ncbi.nlm.nih.gov/pubmed/34805769
http://dx.doi.org/10.1097/HS9.0000000000000666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601272/
https://www.ncbi.nlm.nih.gov/pubmed/34805769
http://dx.doi.org/10.1097/HS9.0000000000000666

Ejemplares similares